Mishima H - Search Results

1

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.

Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N. Suto T, et al. Among authors: mishima h. Int J Clin Oncol. 2017 Jun;22(3):494-504. doi: 10.1007/s10147-016-1083-9. Epub 2017 Jan 11. Int J Clin Oncol. 2017. PMID: 28078540 Free PMC article. Clinical Trial.

2

Use of microsatellite analysis in young patients with colorectal cancer to identify those with hereditary nonpolyposis colorectal cancer.

Ikenaga M, Tomita N, Sekimoto M, Ohue M, Yamamoto H, Miyake Y, Mishima H, Nishisho I, Kikkawa N, Monden M. Ikenaga M, et al. Among authors: mishima h. J Surg Oncol. 2002 Mar;79(3):157-65. doi: 10.1002/jso.10064. J Surg Oncol. 2002. PMID: 11870666

3

A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.

Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K, Tamura T, Takemiya S, Takiuchi H, Nakagawa K, Mishima H. Hyodo I, et al. Among authors: mishima h. Jpn J Clin Oncol. 2006 Jul;36(7):410-7. doi: 10.1093/jjco/hyl058. Epub 2006 Jul 6. Jpn J Clin Oncol. 2006. PMID: 16825251 Clinical Trial.

4

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.

Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, Monden M. Kato T, et al. Among authors: mishima h. Cancer Chemother Pharmacol. 2008 Feb;61(2):275-81. doi: 10.1007/s00280-007-0471-2. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429630 Clinical Trial.

5

Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.

Mishima H, Ikenaga M, Ishida H, Iwamoto S, Morimoto T, Narahara H, Kato T, Tsujie M, Kitai T, Fukunaga M, Nakanishi M, Tsujinaka T, Furukawa H, Taguchi T; Osaka Gastrointestional Cancer Chemotherapy Study Group. Mishima H, et al. Anticancer Res. 2007 Mar-Apr;27(2):1003-8. Anticancer Res. 2007. PMID: 17465234 Free article. Clinical Trial.

6

[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].

Suenaga M, Nishina T, Hyodo I, Munakata M, Koizumi W, Mishima H, Sato A, Mizunuma N, Hatake K. Suenaga M, et al. Among authors: mishima h. Gan To Kagaku Ryoho. 2008 Feb;35(2):255-60. Gan To Kagaku Ryoho. 2008. PMID: 18281761 Clinical Trial. Japanese.

7

Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).

Kono T, Mishima H, Shimada M, Morita S, Sakamoto J; GONE Investigators. Kono T, et al. Among authors: mishima h. Jpn J Clin Oncol. 2009 Dec;39(12):847-9. doi: 10.1093/jjco/hyp100. Epub 2009 Sep 4. Jpn J Clin Oncol. 2009. PMID: 19734172 Clinical Trial.

8

Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.

Oba K, Matsuoka M, Satoh T, Muro K, Oriuchi N, Sakamoto J, Mishima H. Oba K, et al. Among authors: mishima h. Jpn J Clin Oncol. 2011 Jan;41(1):134-8. doi: 10.1093/jjco/hyq165. Epub 2010 Sep 6. Jpn J Clin Oncol. 2011. PMID: 20819834 Clinical Trial.

9

The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.

Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y. Okayama N, et al. Among authors: mishima h. Jpn J Clin Oncol. 2011 Feb;41(2):165-71. doi: 10.1093/jjco/hyq173. Epub 2010 Oct 5. Jpn J Clin Oncol. 2011. PMID: 20926413

10

Does 1 year adjuvant chemotherapy with oral 5-FUs in colon cancer reduce the peak of recurrence in 1 year and provide long-term OS benefit?

Hamada C, Sakamoto J, Satoh T, Sadahiro S, Mishima H, Sugihara K, Saji S, Tomita N. Hamada C, et al. Among authors: mishima h. Jpn J Clin Oncol. 2011 Feb;41(2):299-302. doi: 10.1093/jjco/hyq209. Epub 2010 Nov 17. Jpn J Clin Oncol. 2011. PMID: 21084437

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

676 results

Search Page